Hitgen and Cancer Research UK's Manchester Institute enter licence agreement in lung cancer

(Cancer Research UK) CANCER RESEARCH UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.